Biotechnology

Ironwood Pharma

Ironwood Pharma released FY2026 Q1 earnings on May 7 Pre-Market (EST), actual revenue USD 106.51 M (forecast USD 92.1 M), actual EPS USD 0.24 (forecast USD 0.1633)

Ironwood Pharma to Release FY2026 Q1 Earnings on May 7 Pre-Market EST, Forecast Revenue USD 92.1 M, EPS USD 0.1633

Ironwood Pharma released FY2025 Q4 earnings on February 25 Pre-Market (EST), actual revenue USD 47.71 M (forecast USD 50.93 M), actual EPS USD -0.01 (forecast USD -0.065)

Ironwood Pharma released FY2025 Annual Earnings on February 25 Pre-Market (EST), actual revenue USD 296.15 M (forecast USD 299.23 M), actual EPS USD 0.1483 (forecast USD 0.095)

Ironwood Pharma to release FY2025 Q4 earnings on February 25, 2026, pre-market EST; forecast revenue USD 50.93 M, EPS USD -0.065

Wells Fargo Raises Ironwood Pharmaceuticals Target Price to $5

Citizens Jmp Raises Ironwood Pharmaceuticals' Rating and Target Price by 87.35%

Ironwood Pharma released FY2025 9 Months Earnings on November 10, 2025 (EST) with actual revenue of USD 248.44 M and EPS of USD 0.1344

Ironwood Pharma released FY2025 Q3 earnings on November 10 (EST), actual revenue USD 122.06 M (forecast USD 75.7 M), actual EPS USD 0.2293 (forecast USD 0.1166)

Linzess approved by FDA for pediatric IBS-C treatment

Ironwood Pharma released FY2025 Q2 earnings on August 7 (EST), actual revenue USD 85.24 M (forecast USD 62.02 M), actual EPS USD 0.14 (forecast USD 0.0233)

Ironwood Pharma released FY2025 Semi-Annual earnings on August 7 (EST), actual revenue USD 126.38 M, actual EPS USD -0.09

Ironwood Pharmaceuticals COO Disposes of Common Stock

Ironwood Pharmaceuticals Stock Gets Hold Rating, Earnings Miss Estimates

Ironwood Pharma released FY2025 Q1 earnings on May 7, 2025 (EST), actual revenue USD 41.14 M (forecast USD 56.7 M), actual EPS USD -0.2322 (forecast USD -0.17)

Ironwood Pharmaceuticals Reports Q1 Loss

Ironwood Pharmaceuticals to Participate in Citizens Life Sciences Conference

Ironwood Pharma Reaffirms LINZESS Sales Guidance

Citizens Jmp Downgrades Ironwood Pharmaceuticals Rating, Shares Plunge

Wells Fargo Downgrades Ironwood Pharmaceuticals Rating and Target Price

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

IRWD

UPBD

A new shortlist highlights the top 10 small-cap stocks with low forward P/E and strong profitability, including Ironwood Pharmaceuticals and Upbound Group. However, rising 10-year Treasury yields may negatively impact small caps dependent on debt financing and consumer demand, affecting their valuations. Conversely, sectors like AI infrastructure and energy, represented by Mayville Engineering and Infinity Natural Resources, may benefit from shifts in corporate capital expenditures.

Upbound

Infinity Natural Resources - CL

Mayville Engineering

Small-cap value picks emerge despite rising yield pressures

Earnings Watch

Ironwood Pharma | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 106.51 M

Ironwood Pharma | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 106.51 M

Ironwood Pharmaceuticals reported strong Q1 2026 results, with U.S. net sales of LINZESS reaching $273 million, a 97% increase year-over-year. Total revenue was $107 million, with a GAAP net income of $41 million. The company is on track for a Phase 3 trial of apraglutide and has received FDA priority review for LINZESS in treating functional constipation in young children. The financial performance positions Ironwood well to meet its full-year guidance and support the repayment of convertible notes due in June 2026.

StockTitan

Abbvie

IQVIA

Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance | IRWD Stock News

Ironwood Pharmaceuticals (IRWD) will announce its Q1 earnings on May 7th, with a consensus EPS estimate of $0.24 and revenue estimate of $92.1M. Historically, IRWD has beaten EPS estimates 13% of the time and revenue estimates 50% of the time over the past two years.

Ironwood Pharmaceuticals Q1 2026 earnings preview

Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS) | IRWD Stock News

Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS) | IRWD Stock News

Ironwood Pharma(IRWD.US)

Small-cap value picks emerge despite rising yield pressures

Ironwood Pharma | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 106.51 M

Ironwood Pharma | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 106.51 M

Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance | IRWD Stock News

Ironwood Pharmaceuticals Q1 2026 earnings preview

Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS) | IRWD Stock News